NASDAQ:CTSO Cytosorbents (CTSO) Stock Price, News & Analysis → Bible Shocker: Have You Seen Elon Musk’s Miracle? (From InvestorPlace) (Ad) Free CTSO Stock Alerts $0.97 +0.10 (+11.53%) (As of 05/17/2024 ET) Add Compare Share Share Today's Range$0.85▼$0.9750-Day Range$0.79▼$1.0452-Week Range$0.78▼$4.29Volume228,725 shsAverage Volume113,719 shsMarket Capitalization$52.55 millionP/E RatioN/ADividend YieldN/APrice Target$2.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Cytosorbents alerts: Email Address Cytosorbents MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside106.7% Upside$2.00 Price TargetShort InterestBearish2.85% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.37Based on 6 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.35) to ($0.18) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.97 out of 5 starsMedical Sector777th out of 920 stocksSurgical & Medical Instruments Industry88th out of 99 stocks 3.3 Analyst's Opinion Consensus RatingCytosorbents has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Amount of Analyst CoverageCytosorbents has only been the subject of 2 research reports in the past 90 days.Read more about Cytosorbents' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted2.85% of the outstanding shares of Cytosorbents have been sold short.Short Interest Ratio / Days to CoverCytosorbents has a short interest ratio ("days to cover") of 15.2, which indicates bearish sentiment.Change versus previous month Previous Next 0.0 Dividend Strength Dividend YieldCytosorbents does not currently pay a dividend.Dividend GrowthCytosorbents does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CTSO. Previous Next 2.4 News and Social Media Coverage News SentimentCytosorbents has a news sentiment score of 0.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Cytosorbents this week, compared to 1 article on an average week.Search Interest8 people have searched for CTSO on MarketBeat in the last 30 days. This is an increase of 167% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Cytosorbents to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cytosorbents insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.60% of the stock of Cytosorbents is held by insiders.Percentage Held by InstitutionsOnly 32.87% of the stock of Cytosorbents is held by institutions.Read more about Cytosorbents' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Cytosorbents are expected to grow in the coming year, from ($0.35) to ($0.18) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cytosorbents is -1.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cytosorbents is -1.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCytosorbents has a P/B Ratio of 2.76. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Cytosorbents' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad InvestorPlaceBible Shocker: Have You Seen Elon Musk’s Miracle?Breaking News: Elon Musk Invents New Type of A.I. (Shocking) Elon Musk is about to shock the world again with this new type of A.I.… Minting new millionaires in the process.Click here for the full story… About Cytosorbents Stock (NASDAQ:CTSO)Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.Read More CTSO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CTSO Stock News HeadlinesMay 18 at 3:56 AM | americanbankingnews.comCytosorbents (NASDAQ:CTSO) Coverage Initiated by Analysts at StockNews.comMay 17 at 6:08 AM | americanbankingnews.comCytosorbents (NASDAQ:CTSO) Stock Rating Reaffirmed by B. RileyMay 15, 2024 | finance.yahoo.comCTSO: CytoSorbents reports 1st quarter 2024 financial results and highlighted STAR-T trial data presentation at the AATS conference.May 15, 2024 | finance.yahoo.comCTSO: CytoSorbents Potential for High Margin Revenue Growth Supports Price Target of $4.00May 12, 2024 | finance.yahoo.comCytosorbents First Quarter 2024 Earnings: In Line With ExpectationsMay 10, 2024 | finance.yahoo.comCytosorbents Corporation (NASDAQ:CTSO) Q1 2024 Earnings Call TranscriptMay 10, 2024 | americanbankingnews.comCytosorbents (NASDAQ:CTSO) Coverage Initiated at StockNews.comMay 9, 2024 | globenewswire.comCytoSorbents Reports First Quarter 2024 ResultsMay 9, 2024 | markets.businessinsider.comHere's what Wall Street expects from Cytosorbents's earningsMay 7, 2024 | markets.businessinsider.comHold Rating on Cytosorbents Amid Regulatory Uncertainties and Mixed Clinical ResultsMay 2, 2024 | finance.yahoo.comCytoSorbents May 6, 2024 Virtual KOL and Analyst-Investor Day: STAR-T Pivotal Trial Topline Results & Real World Experience with Antithrombotic Drug Removal in EuropeApril 26, 2024 | globenewswire.comCytoSorbents to Report First Quarter 2024 Operating and Financial ResultsApril 17, 2024 | finance.yahoo.comSTAR-T Pivotal Trial Results to Be Featured as a Late-Breaking Presentation at the 2024 American Association for Thoracic Surgery Annual MeetingApril 4, 2024 | finance.yahoo.comCTSO: CytoSorbents Expects Significant Gross Margin Expansion in 2024.April 4, 2024 | finance.yahoo.comCTSO: CytoSorbents Expects Significant Gross Margin Expansion in 2023.March 16, 2024 | finance.yahoo.comCytosorbents Full Year 2023 Earnings: Misses ExpectationsMarch 16, 2024 | finance.yahoo.comCTSO Apr 2024 2.500 callMarch 15, 2024 | finance.yahoo.comQ4 2023 Cytosorbents Corp Earnings CallMarch 15, 2024 | finance.yahoo.comCytosorbents Corporation (NASDAQ:CTSO) Q4 2023 Earnings Call TranscriptMarch 14, 2024 | benzinga.comRecap: CytoSorbents Q4 EarningsMarch 14, 2024 | globenewswire.comCytoSorbents Reports Fourth Quarter and Full Year 2023 ResultsMarch 13, 2024 | markets.businessinsider.comCytosorbents earnings preview: what to expectMarch 6, 2024 | globenewswire.comCytoSorbents to Report Fiscal 2023 Operating and Financial ResultsMarch 4, 2024 | finance.yahoo.comCTSO Mar 2024 2.500 callFebruary 27, 2024 | money.usnews.comCytosorbents CorpSee More Headlines Receive CTSO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cytosorbents and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today5/19/2024Next Earnings (Estimated)8/06/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:CTSO CUSIPN/A CIK1175151 Webwww.cytosorbents.com Phone(732) 329-8885Fax732-329-8650Employees186Year FoundedN/APrice Target and Rating Average Stock Price Target$2.00 High Stock Price Target$3.00 Low Stock Price Target$1.00 Potential Upside/Downside+106.7%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.59) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-28,510,000.00 Net Margins-75.07% Pretax Margin-77.28% Return on Equity-129.89% Return on Assets-54.98% Debt Debt-to-Equity Ratio0.10 Current Ratio1.49 Quick Ratio1.21 Sales & Book Value Annual Sales$32.16 million Price / Sales1.63 Cash FlowN/A Price / Cash FlowN/A Book Value$0.35 per share Price / Book2.76Miscellaneous Outstanding Shares54,306,000Free Float50,722,000Market Cap$52.55 million OptionableOptionable Beta0.62 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesDr. Phillip P. Chan M.D. (Age 54)Ph.D., CEO & Director Comp: $541.93kMr. Vincent J. Capponi M.S. (Age 66)President & COO Comp: $452.62kMs. Kathleen P. Bloch CPA (Age 69)M.B.A., Chief Financial Officer Comp: $395.43kDr. Efthymios N. Deliargyris FACC (Age 56)FESC, FSCAI, M.D., Chief Medical Officer Comp: $463.15kMs. Terri Anne Powers M.B.A.Vice President of Investor Relations & Corporate CommunicationsDr. Christian Steiner M.D.Executive Vice President of Sales & MarketingMr. Christopher Cramer M.B.A.M.S., Senior Vice President of Business DevelopmentDr. Irina B. Kulinets Ph.D. (Age 69)Senior Vice President of Global Regulatory Affairs Jodi HooverExecutiveDr. Robert H. Bartlett M.D. (Age 85)Co-Chairman of Cardiac Surgery Advisory Board & Consultant Comp: $54kMore ExecutivesKey CompetitorsLENSARNASDAQ:LNSRDaxorNASDAQ:DXRLucid DiagnosticsNASDAQ:LUCDCarmellNASDAQ:CTCXApyx MedicalNASDAQ:APYXView All CompetitorsInsiders & InstitutionsAvenir CorpBought 121,294 shares on 5/16/2024Ownership: 5.842%CM Management LLCBought 410,000 shares on 5/14/2024Ownership: 1.519%Key Client Fiduciary Advisors LLCBought 22,557 shares on 4/15/2024Ownership: 0.064%Alan D SobelBought 22,557 shares on 12/13/2023Total: $30,000.81 ($1.33/share)Michael G BatorBought 2,000 shares on 8/7/2023Total: $6,340.00 ($3.17/share)View All Insider TransactionsView All Institutional Transactions CTSO Stock Analysis - Frequently Asked Questions Should I buy or sell Cytosorbents stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cytosorbents in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" CTSO shares. View CTSO analyst ratings or view top-rated stocks. What is Cytosorbents' stock price target for 2024? 2 Wall Street analysts have issued 1 year price targets for Cytosorbents' shares. Their CTSO share price targets range from $1.00 to $3.00. On average, they expect the company's stock price to reach $2.00 in the next year. This suggests a possible upside of 106.7% from the stock's current price. View analysts price targets for CTSO or view top-rated stocks among Wall Street analysts. How have CTSO shares performed in 2024? Cytosorbents' stock was trading at $1.11 at the beginning of the year. Since then, CTSO stock has decreased by 12.8% and is now trading at $0.9676. View the best growth stocks for 2024 here. When is Cytosorbents' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 6th 2024. View our CTSO earnings forecast. How were Cytosorbents' earnings last quarter? Cytosorbents Co. (NASDAQ:CTSO) issued its quarterly earnings results on Thursday, May, 9th. The medical research company reported ($0.12) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.12). The medical research company had revenue of $9.79 million for the quarter, compared to analyst estimates of $9.78 million. Cytosorbents had a negative net margin of 75.07% and a negative trailing twelve-month return on equity of 129.89%. During the same period in the prior year, the firm posted ($0.17) earnings per share. What is Phillip Chan's approval rating as Cytosorbents' CEO? 11 employees have rated Cytosorbents Chief Executive Officer Phillip Chan on Glassdoor.com. Phillip Chan has an approval rating of 26% among the company's employees. This puts Phillip Chan in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 74.0% of employees surveyed would recommend working at Cytosorbents to a friend. What other stocks do shareholders of Cytosorbents own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cytosorbents investors own include Rekor Systems (REKR), Advanced Micro Devices (AMD), Micron Technology (MU), Gilead Sciences (GILD), Pfizer (PFE), AbbVie (ABBV), Inovio Pharmaceuticals (INO), OPKO Health (OPK) and Sorrento Therapeutics (SRNE). Who are Cytosorbents' major shareholders? Cytosorbents' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Avenir Corp (5.84%), CM Management LLC (1.52%), Key Client Fiduciary Advisors LLC (0.06%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Al Kraus, Alan D Sobel, Edward Raymond Jones, Jiny Kim, Kathleen P Bloch, Michael G Bator, Phillip P Chan and Vincent Capponi. View institutional ownership trends. How do I buy shares of Cytosorbents? Shares of CTSO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CTSO) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersBuy this small stock before coming AI Tidal WaveChaikin AnalyticsCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingShocking $16T Elon Musk Crypto LeakCrypto 101 MediaForget Bitcoin: This $8 Stock Is the Next Big ThingBehind the MarketsDems have chosen Biden replacement?Paradigm PressHow Biden has already won 2024Porter & CompanyExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersA letter is coming from the "Bureau of the Fiscal Service".Stansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cytosorbents Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.